Overview

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter center, 2-arms prospective randomized phase II trial which evaluates whether tocilizumab with gemcitabine/nab-paclitaxel is more effective than gemcitabine/nab-paclitaxel.
Phase:
Phase 2
Details
Lead Sponsor:
Herlev Hospital
Collaborator:
Celgene
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel